The lead scientist at Percheron Therapeutics discussed research on antisense oligonucleotide therapies in mouse models of DMD.
George Tachas, PhD
Advertisement
Articles by George Tachas, PhD
The lead scientist at Percheron Therapeutics discussed a phase 2 blinded study of ATL1102 being conducted in the Europe and Australia.
The lead scientist at Percheron Therapeutics discussed the design of the study assessing proteomics of ATL1102.
The lead scientist at Percheron Therapeutics discussed how ATL1102 could target inflammation as a secondary cause of muscle damage in DMD.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CGTlive®
1
Intellia Puts Phase 3 Trials for Transthyretin Amyloidosis Gene Editing Therapy Nex-Z on Hold Following Grade 4 Liver AE
2
Around the Helix: Cell and Gene Therapy Company Updates – October 29, 2025
3
Guess the Therapy Answer October 29, 2025
4
Quarter Century Update: The Continued Unknowns of Cell and Gene Therapy
5
